{"gene":"DARS1","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":2016,"finding":"DARS1 (cytoplasmic aspartyl-tRNA synthetase) localizes primarily to the cell soma of neurons where it co-localizes with other components of the translation machinery; it is also present along neurites and at synapses, suggesting a role in local protein synthesis. Complete loss of DARS1 (Dars-null) is embryonic lethal in mice (before E11), indicating an essential role in early development.","method":"Immunohistochemistry, immunofluorescence, subcellular fractionation/co-localization, and genetic knockout mouse model","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiments with functional consequence (lethality of null), single lab, multiple orthogonal methods","pmids":["27816769"],"is_preprint":false},{"year":2016,"finding":"Heterozygous Dars1-null mice with substantially reduced DARS1 levels show reduced pre-pulse inhibition of the acoustic startle response, indicating a functional role for DARS1 dosage in attentional processing, even without overt motor abnormalities.","method":"Acoustic startle pre-pulse inhibition testing in heterozygous knockout mice","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KO/hypomorph with specific behavioral phenotype, single lab","pmids":["27816769"],"is_preprint":false},{"year":2021,"finding":"Homozygous Dars1 hypomorphic (point mutation in trans to null allele) mice develop demyelination and vacuolization of spinal cord white matter, with reduced expression of major myelin proteins, establishing that reduced DARS1 enzymatic activity causes hypomyelination pathology consistent with HBSL leukodystrophy.","method":"Hypomorphic mouse model (compound heterozygous Dars1 point mutation / null allele), histopathology, Western blot for myelin proteins","journal":"Frontiers in cellular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function mouse model with specific neuropathological phenotype, single lab, multiple readouts","pmids":["33551752"],"is_preprint":false},{"year":2022,"finding":"Introduction of the pathogenic DARS1 M256L missense mutation (compound heterozygous with null allele) in mice causes developmental delay, hydrocephalus, vacuolization of white matter, and altered energy metabolism (reduced body fat, increased respiratory exchange ratio), demonstrating that the M256L mutation retains only partial enzyme activity and that DARS1 function extends to metabolic regulation beyond the CNS.","method":"Knock-in mouse model (Dars1 M256L/- genotype), histopathology, metabolic phenotyping","journal":"Neurochemical research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic disease-model with multiple defined phenotypic readouts, single lab","pmids":["35357600"],"is_preprint":false},{"year":2021,"finding":"DARS1 (aspartyl-tRNA synthetase) was identified by photoaffinity labeling and LC-MS/MS as a cellular target protein of the anti-HIV compound baculiferin 18. Overexpression and knockdown of DARS1 in HEK293T cells modulated HIV virus infection, supporting DARS1 as a functional regulator of HIV replication.","method":"Photoaffinity labeling, LC-MS/MS proteomics, DARS1 overexpression and knockdown in HEK293T cells, antiviral assay, molecular docking","journal":"ACS chemical biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — photoaffinity pulldown with MS identification plus gain/loss-of-function validation, single lab, multiple orthogonal methods","pmids":["34338505"],"is_preprint":false},{"year":2026,"finding":"DARS1 protein was detected in the nucleus of hepatocellular carcinoma cells where it interacts with members of the SAGA transcriptional co-activator complex (including SUPT7L), representing a non-canonical function beyond tRNA aminoacylation. DARS1 depletion reduced MYC protein levels and increased its phosphorylation, linking DARS1-SAGA interaction to MYC-driven oncogenic signaling.","method":"Quantitative proteomics of DARS1 protein interactors, biochemical co-immunoprecipitation, nuclear fractionation, Western blot for MYC and phospho-MYC; genetic and pharmacological DARS1 modulation in liver cancer cells and xenograft/orthotopic models","journal":"Hepatology (Baltimore, Md.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative proteomics plus biochemical confirmation plus functional in vivo validation, single lab, multiple orthogonal methods","pmids":["41790991"],"is_preprint":false},{"year":2026,"finding":"DARS1 overexpression in HCC cells reshapes the cellular proteome with significant enrichment of high-aspartate content proteins, consistent with its canonical role as aspartyl-tRNA synthetase influencing translational output in a substrate-dependent manner.","method":"Quantitative proteomic profiling of DARS1-overexpressing versus control HCC cells","journal":"Hepatology (Baltimore, Md.)","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — proteomic reconstitution in cell lines with quantitative profiling, single lab","pmids":["41790991"],"is_preprint":false},{"year":2026,"finding":"DARS1 depletion in human MPN cell models suppresses proliferation and xenograft tumor growth, induces cell-cycle arrest, and promotes apoptosis. Integrated transcriptomic and metabolomic analyses identified alterations in calcium signaling, pyrimidine metabolism, and nucleotide metabolism, and reactivation of PI3K/AKT partially rescued the proliferative phenotype, placing DARS1 upstream of PI3K/AKT in MPN cells.","method":"siRNA/genetic depletion of DARS1 in MPN cell lines, xenograft models, transcriptomics, metabolomics, PI3K/AKT rescue experiments","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined phenotype, multi-omics, epistasis rescue experiment, single lab","pmids":["42177774"],"is_preprint":false}],"current_model":"DARS1 encodes the cytoplasmic aspartyl-tRNA synthetase that charges tRNA with aspartate; it is essential for early embryonic development (null is lethal in mice), is enriched in neurons where it localizes to soma, neurites and synapses (consistent with local translation), and its partial loss-of-function causes hypomyelination/leukodystrophy (HBSL) in mice and humans. Beyond its canonical aminoacylation role, DARS1 reshapes the cellular proteome in cancer cells, interacts non-canonically with the nuclear SAGA transcriptional co-activator complex to modulate MYC activity in hepatocellular carcinoma, functions upstream of PI3K/AKT in myeloproliferative neoplasm cells, and has been identified as a cellular target of anti-HIV compounds that modulate viral replication."},"narrative":{"mechanistic_narrative":"DARS1 is the cytoplasmic aspartyl-tRNA synthetase whose aminoacylation activity is essential for early development—complete loss is embryonic lethal in mice—and whose dosage and enzymatic competence shape neuronal protein synthesis and myelination [PMID:27816769, PMID:33551752]. In neurons the enzyme concentrates in the soma alongside the translation machinery and extends into neurites and synapses, consistent with a role in local protein synthesis [PMID:27816769], while reduced enzyme activity from hypomorphic and pathogenic point alleles (e.g. M256L) produces white-matter vacuolization, demyelination with loss of major myelin proteins, and systemic metabolic alterations, recapitulating HBSL leukodystrophy [PMID:33551752, PMID:35357600]. The aminoacylation function also tunes translational output in a substrate-biased manner: DARS1 overexpression in hepatocellular carcinoma cells reshapes the proteome toward high-aspartate-content proteins [PMID:41790991]. Beyond canonical charging, DARS1 has non-canonical roles—it localizes to the nucleus of HCC cells where it associates with the SAGA co-activator complex (including SUPT7L) to sustain MYC protein levels and oncogenic signaling [PMID:41790991], and in myeloproliferative neoplasm cells it acts upstream of PI3K/AKT to drive proliferation and survival [PMID:42177774]. It has additionally been identified as a cellular target of an anti-HIV compound that modulates viral replication [PMID:34338505].","teleology":[{"year":2016,"claim":"Established that DARS1 is developmentally essential and positioned in neurons where local translation occurs, framing it as more than a housekeeping enzyme.","evidence":"Immunohistochemistry, immunofluorescence and subcellular fractionation plus a Dars-null knockout mouse","pmids":["27816769"],"confidence":"Medium","gaps":["Embryonic lethality of the null prevents dissection of tissue-specific requirements","Co-localization with translation machinery does not directly demonstrate local aminoacylation at synapses"]},{"year":2016,"claim":"Showed DARS1 dosage influences neural function, as heterozygous hypomorphs have behavioral (pre-pulse inhibition) deficits absent overt motor pathology.","evidence":"Acoustic startle pre-pulse inhibition testing in heterozygous knockout mice","pmids":["27816769"],"confidence":"Medium","gaps":["Molecular basis linking reduced DARS1 to attentional processing not defined","Single behavioral readout"]},{"year":2021,"claim":"Demonstrated causally that reduced DARS1 enzymatic activity drives hypomyelination pathology, modeling HBSL leukodystrophy.","evidence":"Compound heterozygous hypomorphic point-mutation/null mouse, histopathology and Western blot for myelin proteins","pmids":["33551752"],"confidence":"Medium","gaps":["Mechanism connecting aminoacylation deficit to selective myelin protein loss unresolved","Cell-type origin of demyelination not pinpointed"]},{"year":2022,"claim":"Extended DARS1 function beyond the CNS by showing a pathogenic M256L allele with partial activity causes developmental, structural, and metabolic phenotypes.","evidence":"Dars1 M256L/- knock-in mouse with histopathology and metabolic phenotyping","pmids":["35357600"],"confidence":"Medium","gaps":["Mechanism linking aminoacylation to altered energy metabolism unknown","Whether metabolic effects are secondary to systemic illness untested"]},{"year":2021,"claim":"Identified DARS1 as a druggable cellular target whose levels modulate HIV replication, a function outside canonical translation.","evidence":"Photoaffinity labeling and LC-MS/MS with DARS1 overexpression/knockdown in HEK293T antiviral assays","pmids":["34338505"],"confidence":"Medium","gaps":["Mechanism by which DARS1 affects viral replication not defined","Direct compound-binding site only inferred by docking"]},{"year":2026,"claim":"Revealed a non-canonical nuclear role: DARS1 associates with the SAGA co-activator complex to sustain MYC-driven oncogenic signaling in hepatocellular carcinoma.","evidence":"Quantitative interactor proteomics, co-IP, nuclear fractionation, phospho-MYC Western blot, and in vivo xenograft/orthotopic models","pmids":["41790991"],"confidence":"Medium","gaps":["Whether SAGA association requires aminoacylation activity unknown","Direct vs indirect nature of the DARS1-SUPT7L interaction not resolved"]},{"year":2026,"claim":"Connected DARS1 aminoacylation to proteome composition, showing overexpression biases translation toward high-aspartate-content proteins.","evidence":"Quantitative proteomic profiling of DARS1-overexpressing versus control HCC cells","pmids":["41790991"],"confidence":"Medium","gaps":["Causal link between aspartate-tRNA charging rate and enriched protein set not directly tested","Single cell-line context"]},{"year":2026,"claim":"Placed DARS1 upstream of PI3K/AKT signaling in myeloproliferative neoplasm cells, defining a proliferation/survival pathway dependence.","evidence":"DARS1 depletion in MPN cell lines and xenografts, transcriptomics/metabolomics, and PI3K/AKT reactivation rescue","pmids":["42177774"],"confidence":"Medium","gaps":["Molecular mechanism by which DARS1 engages PI3K/AKT undefined","Whether the effect requires aminoacylation activity untested"]},{"year":null,"claim":"It remains unknown whether DARS1's non-canonical nuclear, signaling, and antiviral activities depend on its aminoacylation catalytic function or represent moonlighting roles.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No catalytic-dead separation-of-function experiments reported","Structural basis for SAGA or compound interaction not determined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,2,6]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[0,6]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[5]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,6]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,3]}],"complexes":["SAGA complex"],"partners":["SUPT7L"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P14868","full_name":"Aspartate--tRNA ligase, cytoplasmic","aliases":["Aspartyl-tRNA synthetase","AspRS","Cell proliferation-inducing gene 40 protein"],"length_aa":501,"mass_kda":57.1,"function":"Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA","subcellular_location":"Cytoplasm, cytosol","url":"https://www.uniprot.org/uniprotkb/P14868/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/DARS1","classification":"Common Essential","n_dependent_lines":1203,"n_total_lines":1208,"dependency_fraction":0.9958609271523179},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CAPRIN1","stoichiometry":0.2},{"gene":"CAPZB","stoichiometry":0.2},{"gene":"DRG1","stoichiometry":0.2},{"gene":"EMC8","stoichiometry":0.2},{"gene":"EMC9","stoichiometry":0.2},{"gene":"NCAPH","stoichiometry":0.2},{"gene":"RACK1","stoichiometry":0.2},{"gene":"RBM8A","stoichiometry":0.2},{"gene":"RPS16","stoichiometry":0.2},{"gene":"SRP68","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/DARS1","total_profiled":1310},"omim":[{"mim_id":"615281","title":"HYPOMYELINATION WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LEG SPASTICITY; HBSL","url":"https://www.omim.org/entry/615281"},{"mim_id":"603084","title":"ASPARTYL-tRNA SYNTHETASE 1; DARS1","url":"https://www.omim.org/entry/603084"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Cytosol","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/DARS1"},"hgnc":{"alias_symbol":[],"prev_symbol":["DARS"]},"alphafold":{"accession":"P14868","domains":[{"cath_id":"2.40.50.140","chopping":"28-145","consensus_level":"high","plddt":97.7496,"start":28,"end":145},{"cath_id":"-","chopping":"155-188","consensus_level":"medium","plddt":84.9971,"start":155,"end":188},{"cath_id":"3.30.930.10","chopping":"190-487","consensus_level":"high","plddt":96.0151,"start":190,"end":487}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P14868","model_url":"https://alphafold.ebi.ac.uk/files/AF-P14868-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P14868-F1-predicted_aligned_error_v6.png","plddt_mean":93.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=DARS1","jax_strain_url":"https://www.jax.org/strain/search?query=DARS1"},"sequence":{"accession":"P14868","fasta_url":"https://rest.uniprot.org/uniprotkb/P14868.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P14868/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P14868"}},"corpus_meta":[{"pmid":"18676649","id":"PMC_18676649","title":"DARS (Decoys As the Reference State) potentials for protein-protein docking.","date":"2008","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/18676649","citation_count":128,"is_preprint":false},{"pmid":"21851628","id":"PMC_21851628","title":"DARS-RNP and QUASI-RNP: new statistical potentials for protein-RNA docking.","date":"2011","source":"BMC bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21851628","citation_count":84,"is_preprint":false},{"pmid":"31289203","id":"PMC_31289203","title":"Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy.","date":"2019","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/31289203","citation_count":61,"is_preprint":false},{"pmid":"35688263","id":"PMC_35688263","title":"Exosomes deliver lncRNA DARS-AS1 siRNA to inhibit chronic unpredictable mild stress-induced TNBC metastasis.","date":"2022","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/35688263","citation_count":59,"is_preprint":false},{"pmid":"25527264","id":"PMC_25527264","title":"DARS-associated leukoencephalopathy can mimic a steroid-responsive neuroinflammatory disorder.","date":"2014","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25527264","citation_count":57,"is_preprint":false},{"pmid":"37544559","id":"PMC_37544559","title":"CL4-modified exosomes deliver lncRNA DARS-AS1 siRNA to suppress triple-negative breast cancer progression and attenuate doxorubicin resistance by inhibiting autophagy.","date":"2023","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/37544559","citation_count":40,"is_preprint":false},{"pmid":"37540752","id":"PMC_37540752","title":"Multiomics analyses reveal DARS1-AS1/YBX1-controlled posttranscriptional circuits promoting glioblastoma tumorigenesis/radioresistance.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/37540752","citation_count":39,"is_preprint":false},{"pmid":"32526457","id":"PMC_32526457","title":"DARS-AS1 promotes clear cell renal cell carcinoma by sequestering miR-194-5p to up-regulate DARS.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/32526457","citation_count":36,"is_preprint":false},{"pmid":"34644678","id":"PMC_34644678","title":"Potentiated lung adenocarcinoma (LUAD) cell growth, migration and invasion by lncRNA DARS-AS1 via miR-188-5p/ KLF12 axis.","date":"2021","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/34644678","citation_count":33,"is_preprint":false},{"pmid":"35638109","id":"PMC_35638109","title":"DARS-AS1 recruits METTL3/METTL14 to bind and enhance DARS mRNA m6A modification and translation for cytoprotective autophagy in cervical cancer.","date":"2022","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/35638109","citation_count":31,"is_preprint":false},{"pmid":"31841198","id":"PMC_31841198","title":"LncRNA DARS-AS1 regulates microRNA-129 to promote malignant progression of thyroid cancer.","date":"2019","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31841198","citation_count":31,"is_preprint":false},{"pmid":"34596006","id":"PMC_34596006","title":"LncRNA DARS-AS1 aggravates the growth and metastasis of hepatocellular carcinoma via regulating the miR-3200-5p-Cytoskeleton associated protein 2 (CKAP2) axis.","date":"2021","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/34596006","citation_count":28,"is_preprint":false},{"pmid":"33634536","id":"PMC_33634536","title":"Upregulation of lncRNA DARS-AS1 accelerates tumor malignancy in cervical cancer by activating cGMP-PKG pathway.","date":"2021","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/33634536","citation_count":27,"is_preprint":false},{"pmid":"30964159","id":"PMC_30964159","title":"Long noncoding RNA DARS-AS1 acts as an oncogene by targeting miR-532-3p in ovarian cancer.","date":"2019","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30964159","citation_count":24,"is_preprint":false},{"pmid":"29615866","id":"PMC_29615866","title":"Expression Pattern of the Aspartyl-tRNA Synthetase DARS in the Human Brain.","date":"2018","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/29615866","citation_count":22,"is_preprint":false},{"pmid":"27816769","id":"PMC_27816769","title":"In vivocharacterization of the aspartyl-tRNA synthetase DARS: Homing in on the leukodystrophy HBSL.","date":"2016","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/27816769","citation_count":22,"is_preprint":false},{"pmid":"33073700","id":"PMC_33073700","title":"Oncogenic Long Noncoding RNA DARS-AS1 in Childhood Acute Myeloid Leukemia by Binding to microRNA-425.","date":"2020","source":"Technology in cancer research & treatment","url":"https://pubmed.ncbi.nlm.nih.gov/33073700","citation_count":18,"is_preprint":false},{"pmid":"33292218","id":"PMC_33292218","title":"DARS-AS1 accelerates the proliferation of cervical cancer cells via miR-628-5p/JAG1 axis to activate Notch pathway.","date":"2020","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/33292218","citation_count":18,"is_preprint":false},{"pmid":"34328246","id":"PMC_34328246","title":"Long noncoding RNA DARS-AS1 regulates TP53 ubiquitination and affects ovarian cancer progression by modulation miR-194-5p/RBX1 axis.","date":"2021","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/34328246","citation_count":16,"is_preprint":false},{"pmid":"36568518","id":"PMC_36568518","title":"DARS-AS1 modulates cell proliferation and migration of gastric cancer cells by regulating miR-330-3p/NAT10 axis.","date":"2022","source":"Open medicine (Warsaw, Poland)","url":"https://pubmed.ncbi.nlm.nih.gov/36568518","citation_count":11,"is_preprint":false},{"pmid":"33658798","id":"PMC_33658798","title":"Downregulation of LncRNA DARS-AS1 Inhibits the Tumorigenesis of Cervical Cancer via Inhibition of IGF2BP3.","date":"2021","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33658798","citation_count":11,"is_preprint":false},{"pmid":"35422889","id":"PMC_35422889","title":"lncRNA DARS-AS1 Promoted Osteosarcoma Progression through Regulating miR-532-3p/CCR7.","date":"2022","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/35422889","citation_count":10,"is_preprint":false},{"pmid":"35357600","id":"PMC_35357600","title":"Developmental delay and late onset HBSL pathology in hypomorphic Dars1M256L mice.","date":"2022","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/35357600","citation_count":10,"is_preprint":false},{"pmid":"33551752","id":"PMC_33551752","title":"A Hypomorphic Dars1  Model Recapitulates Key Aspects of the Leukodystrophy HBSL.","date":"2021","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/33551752","citation_count":10,"is_preprint":false},{"pmid":"33176595","id":"PMC_33176595","title":"DARS-AS1 Knockdown Inhibits the Growth of Cervical Cancer Cells via Downregulating HMGB1 via Sponging miR-188-5p.","date":"2020","source":"Technology in cancer research & treatment","url":"https://pubmed.ncbi.nlm.nih.gov/33176595","citation_count":9,"is_preprint":false},{"pmid":"38289172","id":"PMC_38289172","title":"Silencing lncRNA-DARS-AS1 suppresses nonsmall cell lung cancer progression by stimulating miR-302a-3p to inhibit ACAT1 expression.","date":"2024","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/38289172","citation_count":8,"is_preprint":false},{"pmid":"25234473","id":"PMC_25234473","title":"darR and darS are regulatory genes that modulate 2-hexyl, 5-propyl resorcinol transcription in Pseudomonas chlororaphis PCL1606.","date":"2014","source":"Microbiology (Reading, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25234473","citation_count":7,"is_preprint":false},{"pmid":"32706049","id":"PMC_32706049","title":"Long noncoding RNA DARS-AS1 acts as an oncogene by targeting miR-532-3p in ovarian cancer.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32706049","citation_count":7,"is_preprint":false},{"pmid":"29518832","id":"PMC_29518832","title":"[DARS mutations responsible for hypomyelination with brain stem and spinal cord involvement and leg spasticity: report of two cases and review of literature].","date":"2018","source":"Zhonghua er ke za zhi = Chinese journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/29518832","citation_count":6,"is_preprint":false},{"pmid":"32982430","id":"PMC_32982430","title":"Long Non-Coding RNA DARS-AS1 Contributes to Prostate Cancer Progression Through Regulating the MicroRNA-628-5p/MTDH Axis.","date":"2020","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/32982430","citation_count":6,"is_preprint":false},{"pmid":"39030308","id":"PMC_39030308","title":"DARS expression in BCR/ABL1-negative myeloproliferative neoplasms and its association with the immune microenvironment.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39030308","citation_count":4,"is_preprint":false},{"pmid":"35970927","id":"PMC_35970927","title":"Long non-coding RNA DARS-AS1 promotes tumor progression by directly suppressing PACT-mediated cellular stress.","date":"2022","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/35970927","citation_count":4,"is_preprint":false},{"pmid":"36712860","id":"PMC_36712860","title":"Leukoencephalopathy hypomyelination with brainstem and spinal cord involvement and leg spasticity caused by DARS1 mutations.","date":"2023","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36712860","citation_count":3,"is_preprint":false},{"pmid":"35571067","id":"PMC_35571067","title":"Case Report: DARS Mutations Responsible for Hypomyelination With Brain Stem and Spinal Cord Involvement and Leg Spasticity.","date":"2022","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35571067","citation_count":3,"is_preprint":false},{"pmid":"37693148","id":"PMC_37693148","title":"hsa_circ_0000519 promotes the progression of lung adenocarcinoma through the hsa-miR-1296-5p/DARS axis.","date":"2023","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/37693148","citation_count":3,"is_preprint":false},{"pmid":"36187230","id":"PMC_36187230","title":"lncRNA DARS-AS1 Modulates TSPAN1-Mediated ITGA2 Hypomethylation by Interaction with miR-194-5p Thus Promoting Ovarian Cancer Progression.","date":"2022","source":"Stem cells international","url":"https://pubmed.ncbi.nlm.nih.gov/36187230","citation_count":3,"is_preprint":false},{"pmid":"34338505","id":"PMC_34338505","title":"Anti-HIV Effects of Baculiferins Are Regulated by the Potential Target Protein DARS.","date":"2021","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/34338505","citation_count":3,"is_preprint":false},{"pmid":"27871331","id":"PMC_27871331","title":"Association of DARS gene polymorphisms with the risk of isolated ventricular septal defects in the Chinese Han population.","date":"2016","source":"Italian journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/27871331","citation_count":2,"is_preprint":false},{"pmid":"38762015","id":"PMC_38762015","title":"LncRNA DARS-AS1 in human cancers: A comprehensive review of its potency as a biomarker and therapeutic target.","date":"2024","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/38762015","citation_count":1,"is_preprint":false},{"pmid":"39412914","id":"PMC_39412914","title":"Can dysphagia aspiration related structures (DARS) be spared in patients with oropharyngeal cancers? Dosimetric evaluation in a prospective study of DARS optimized intensity modulated radiation therapy.","date":"2024","source":"Journal of cancer research and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/39412914","citation_count":1,"is_preprint":false},{"pmid":"41563498","id":"PMC_41563498","title":"The GC-derived exosomal LncRNA DARS-AS1 activates Wnt/β-catenin pathway to drive angiogenesis by regulating miR-605-5p/BCL9.","date":"2026","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41563498","citation_count":0,"is_preprint":false},{"pmid":"41790991","id":"PMC_41790991","title":"Aspartyl-tRNA synthetase 1 (DARS1) reshapes hepatocellular carcinoma proteome and promotes aggressiveness through non-canonical SAGA-MYC signalling modulation.","date":"2026","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/41790991","citation_count":0,"is_preprint":false},{"pmid":"41888419","id":"PMC_41888419","title":"DARS expression in JAK2V617F-positive myeloproliferative neoplasms: immunohistochemical analysis and clinical associations.","date":"2026","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/41888419","citation_count":0,"is_preprint":false},{"pmid":"42177774","id":"PMC_42177774","title":"Integrated transcriptomic and metabolomic analyses provide mechanistic insights into the pro-proliferative role of DARS in human MPN cell models.","date":"2026","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/42177774","citation_count":0,"is_preprint":false},{"pmid":"35958949","id":"PMC_35958949","title":"Long Non-Coding RNA DARS-AS1 Contributes to Prostate Cancer Progression Through Regulating the MicroRNA-628-5p/MTDH Axis [Retraction].","date":"2022","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/35958949","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.31.685903","title":"Single Nucleus MultiOmics Links Novel Transcription Factor Motifs to Murine Hepatic Sex Differences in Chromatin Accessibility and Metabolic Dysfunction-Associated Steatotic Liver Disease","date":"2025-10-31","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.31.685903","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.01.04.631302","title":"Chromatin Changes Associated with Neutrophil Extracellular Trap (NET) Formation in Whole Blood Reflect Complex Immune Signaling","date":"2025-01-04","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.04.631302","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":26849,"output_tokens":2092,"usd":0.055963,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9121,"output_tokens":2674,"usd":0.056227,"stage2_stop_reason":"end_turn"},"total_usd":0.11219,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2016,\n      \"finding\": \"DARS1 (cytoplasmic aspartyl-tRNA synthetase) localizes primarily to the cell soma of neurons where it co-localizes with other components of the translation machinery; it is also present along neurites and at synapses, suggesting a role in local protein synthesis. Complete loss of DARS1 (Dars-null) is embryonic lethal in mice (before E11), indicating an essential role in early development.\",\n      \"method\": \"Immunohistochemistry, immunofluorescence, subcellular fractionation/co-localization, and genetic knockout mouse model\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiments with functional consequence (lethality of null), single lab, multiple orthogonal methods\",\n      \"pmids\": [\"27816769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Heterozygous Dars1-null mice with substantially reduced DARS1 levels show reduced pre-pulse inhibition of the acoustic startle response, indicating a functional role for DARS1 dosage in attentional processing, even without overt motor abnormalities.\",\n      \"method\": \"Acoustic startle pre-pulse inhibition testing in heterozygous knockout mice\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO/hypomorph with specific behavioral phenotype, single lab\",\n      \"pmids\": [\"27816769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Homozygous Dars1 hypomorphic (point mutation in trans to null allele) mice develop demyelination and vacuolization of spinal cord white matter, with reduced expression of major myelin proteins, establishing that reduced DARS1 enzymatic activity causes hypomyelination pathology consistent with HBSL leukodystrophy.\",\n      \"method\": \"Hypomorphic mouse model (compound heterozygous Dars1 point mutation / null allele), histopathology, Western blot for myelin proteins\",\n      \"journal\": \"Frontiers in cellular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function mouse model with specific neuropathological phenotype, single lab, multiple readouts\",\n      \"pmids\": [\"33551752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Introduction of the pathogenic DARS1 M256L missense mutation (compound heterozygous with null allele) in mice causes developmental delay, hydrocephalus, vacuolization of white matter, and altered energy metabolism (reduced body fat, increased respiratory exchange ratio), demonstrating that the M256L mutation retains only partial enzyme activity and that DARS1 function extends to metabolic regulation beyond the CNS.\",\n      \"method\": \"Knock-in mouse model (Dars1 M256L/- genotype), histopathology, metabolic phenotyping\",\n      \"journal\": \"Neurochemical research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic disease-model with multiple defined phenotypic readouts, single lab\",\n      \"pmids\": [\"35357600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"DARS1 (aspartyl-tRNA synthetase) was identified by photoaffinity labeling and LC-MS/MS as a cellular target protein of the anti-HIV compound baculiferin 18. Overexpression and knockdown of DARS1 in HEK293T cells modulated HIV virus infection, supporting DARS1 as a functional regulator of HIV replication.\",\n      \"method\": \"Photoaffinity labeling, LC-MS/MS proteomics, DARS1 overexpression and knockdown in HEK293T cells, antiviral assay, molecular docking\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — photoaffinity pulldown with MS identification plus gain/loss-of-function validation, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"34338505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"DARS1 protein was detected in the nucleus of hepatocellular carcinoma cells where it interacts with members of the SAGA transcriptional co-activator complex (including SUPT7L), representing a non-canonical function beyond tRNA aminoacylation. DARS1 depletion reduced MYC protein levels and increased its phosphorylation, linking DARS1-SAGA interaction to MYC-driven oncogenic signaling.\",\n      \"method\": \"Quantitative proteomics of DARS1 protein interactors, biochemical co-immunoprecipitation, nuclear fractionation, Western blot for MYC and phospho-MYC; genetic and pharmacological DARS1 modulation in liver cancer cells and xenograft/orthotopic models\",\n      \"journal\": \"Hepatology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative proteomics plus biochemical confirmation plus functional in vivo validation, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"41790991\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"DARS1 overexpression in HCC cells reshapes the cellular proteome with significant enrichment of high-aspartate content proteins, consistent with its canonical role as aspartyl-tRNA synthetase influencing translational output in a substrate-dependent manner.\",\n      \"method\": \"Quantitative proteomic profiling of DARS1-overexpressing versus control HCC cells\",\n      \"journal\": \"Hepatology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — proteomic reconstitution in cell lines with quantitative profiling, single lab\",\n      \"pmids\": [\"41790991\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"DARS1 depletion in human MPN cell models suppresses proliferation and xenograft tumor growth, induces cell-cycle arrest, and promotes apoptosis. Integrated transcriptomic and metabolomic analyses identified alterations in calcium signaling, pyrimidine metabolism, and nucleotide metabolism, and reactivation of PI3K/AKT partially rescued the proliferative phenotype, placing DARS1 upstream of PI3K/AKT in MPN cells.\",\n      \"method\": \"siRNA/genetic depletion of DARS1 in MPN cell lines, xenograft models, transcriptomics, metabolomics, PI3K/AKT rescue experiments\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined phenotype, multi-omics, epistasis rescue experiment, single lab\",\n      \"pmids\": [\"42177774\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"DARS1 encodes the cytoplasmic aspartyl-tRNA synthetase that charges tRNA with aspartate; it is essential for early embryonic development (null is lethal in mice), is enriched in neurons where it localizes to soma, neurites and synapses (consistent with local translation), and its partial loss-of-function causes hypomyelination/leukodystrophy (HBSL) in mice and humans. Beyond its canonical aminoacylation role, DARS1 reshapes the cellular proteome in cancer cells, interacts non-canonically with the nuclear SAGA transcriptional co-activator complex to modulate MYC activity in hepatocellular carcinoma, functions upstream of PI3K/AKT in myeloproliferative neoplasm cells, and has been identified as a cellular target of anti-HIV compounds that modulate viral replication.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"DARS1 is the cytoplasmic aspartyl-tRNA synthetase whose aminoacylation activity is essential for early development—complete loss is embryonic lethal in mice—and whose dosage and enzymatic competence shape neuronal protein synthesis and myelination [#0, #2]. In neurons the enzyme concentrates in the soma alongside the translation machinery and extends into neurites and synapses, consistent with a role in local protein synthesis [#0], while reduced enzyme activity from hypomorphic and pathogenic point alleles (e.g. M256L) produces white-matter vacuolization, demyelination with loss of major myelin proteins, and systemic metabolic alterations, recapitulating HBSL leukodystrophy [#2, #3]. The aminoacylation function also tunes translational output in a substrate-biased manner: DARS1 overexpression in hepatocellular carcinoma cells reshapes the proteome toward high-aspartate-content proteins [#6]. Beyond canonical charging, DARS1 has non-canonical roles—it localizes to the nucleus of HCC cells where it associates with the SAGA co-activator complex (including SUPT7L) to sustain MYC protein levels and oncogenic signaling [#5], and in myeloproliferative neoplasm cells it acts upstream of PI3K/AKT to drive proliferation and survival [#7]. It has additionally been identified as a cellular target of an anti-HIV compound that modulates viral replication [#4].\",\n  \"teleology\": [\n    {\n      \"year\": 2016,\n      \"claim\": \"Established that DARS1 is developmentally essential and positioned in neurons where local translation occurs, framing it as more than a housekeeping enzyme.\",\n      \"evidence\": \"Immunohistochemistry, immunofluorescence and subcellular fractionation plus a Dars-null knockout mouse\",\n      \"pmids\": [\"27816769\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Embryonic lethality of the null prevents dissection of tissue-specific requirements\", \"Co-localization with translation machinery does not directly demonstrate local aminoacylation at synapses\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed DARS1 dosage influences neural function, as heterozygous hypomorphs have behavioral (pre-pulse inhibition) deficits absent overt motor pathology.\",\n      \"evidence\": \"Acoustic startle pre-pulse inhibition testing in heterozygous knockout mice\",\n      \"pmids\": [\"27816769\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis linking reduced DARS1 to attentional processing not defined\", \"Single behavioral readout\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated causally that reduced DARS1 enzymatic activity drives hypomyelination pathology, modeling HBSL leukodystrophy.\",\n      \"evidence\": \"Compound heterozygous hypomorphic point-mutation/null mouse, histopathology and Western blot for myelin proteins\",\n      \"pmids\": [\"33551752\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism connecting aminoacylation deficit to selective myelin protein loss unresolved\", \"Cell-type origin of demyelination not pinpointed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended DARS1 function beyond the CNS by showing a pathogenic M256L allele with partial activity causes developmental, structural, and metabolic phenotypes.\",\n      \"evidence\": \"Dars1 M256L/- knock-in mouse with histopathology and metabolic phenotyping\",\n      \"pmids\": [\"35357600\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking aminoacylation to altered energy metabolism unknown\", \"Whether metabolic effects are secondary to systemic illness untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified DARS1 as a druggable cellular target whose levels modulate HIV replication, a function outside canonical translation.\",\n      \"evidence\": \"Photoaffinity labeling and LC-MS/MS with DARS1 overexpression/knockdown in HEK293T antiviral assays\",\n      \"pmids\": [\"34338505\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which DARS1 affects viral replication not defined\", \"Direct compound-binding site only inferred by docking\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Revealed a non-canonical nuclear role: DARS1 associates with the SAGA co-activator complex to sustain MYC-driven oncogenic signaling in hepatocellular carcinoma.\",\n      \"evidence\": \"Quantitative interactor proteomics, co-IP, nuclear fractionation, phospho-MYC Western blot, and in vivo xenograft/orthotopic models\",\n      \"pmids\": [\"41790991\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether SAGA association requires aminoacylation activity unknown\", \"Direct vs indirect nature of the DARS1-SUPT7L interaction not resolved\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Connected DARS1 aminoacylation to proteome composition, showing overexpression biases translation toward high-aspartate-content proteins.\",\n      \"evidence\": \"Quantitative proteomic profiling of DARS1-overexpressing versus control HCC cells\",\n      \"pmids\": [\"41790991\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal link between aspartate-tRNA charging rate and enriched protein set not directly tested\", \"Single cell-line context\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Placed DARS1 upstream of PI3K/AKT signaling in myeloproliferative neoplasm cells, defining a proliferation/survival pathway dependence.\",\n      \"evidence\": \"DARS1 depletion in MPN cell lines and xenografts, transcriptomics/metabolomics, and PI3K/AKT reactivation rescue\",\n      \"pmids\": [\"42177774\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism by which DARS1 engages PI3K/AKT undefined\", \"Whether the effect requires aminoacylation activity untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unknown whether DARS1's non-canonical nuclear, signaling, and antiviral activities depend on its aminoacylation catalytic function or represent moonlighting roles.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No catalytic-dead separation-of-function experiments reported\", \"Structural basis for SAGA or compound interaction not determined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 2, 6]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [0, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 6]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"complexes\": [\"SAGA complex\"],\n    \"partners\": [\"SUPT7L\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}